Zacks Investment Research downgraded shares of NEUROMETRIX INC (NURO) from N/A to NEUTRAL on May 15, 2013, with a target price of $2.10.
Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NEUROMETRIX INC (NURO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment